Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Treasury Shares (2019 - 2025)

Historic Treasury Shares for Kymera Therapeutics (KYMR) over the last 7 years, with Q3 2025 value amounting to $1.4 million.

  • Kymera Therapeutics' Treasury Shares rose 7439.3% to $1.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 million, marking a year-over-year increase of 7439.3%. This contributed to the annual value of $749604.0 for FY2024, which is 2637.89% up from last year.
  • Per Kymera Therapeutics' latest filing, its Treasury Shares stood at $1.4 million for Q3 2025, which was up 7439.3% from $1.3 million recorded in Q2 2025.
  • Kymera Therapeutics' Treasury Shares' 5-year high stood at $1.4 million during Q3 2025, with a 5-year trough of $37745.0 in Q4 2021.
  • For the 5-year period, Kymera Therapeutics' Treasury Shares averaged around $529708.1, with its median value being $467092.0 (2023).
  • As far as peak fluctuations go, Kymera Therapeutics' Treasury Shares plummeted by 6571.88% in 2021, and later soared by 64670.29% in 2022.
  • Over the past 5 years, Kymera Therapeutics' Treasury Shares (Quarter) stood at $37745.0 in 2021, then soared by 646.7% to $281843.0 in 2022, then skyrocketed by 110.45% to $593140.0 in 2023, then increased by 26.38% to $749604.0 in 2024, then surged by 82.23% to $1.4 million in 2025.
  • Its last three reported values are $1.4 million in Q3 2025, $1.3 million for Q2 2025, and $1.2 million during Q1 2025.